ASCO gastrointestinal cancers symposium: Perspectives on older adults with gastrointestinal malignancies
نویسندگان
چکیده
منابع مشابه
ASCO-update: gastrointestinal tumors
A multitude of new molecular and immunologic insights into gastrointestinal tumors have been presented at the ASCO meeting 2017; however, we have focused our update on practice-changing phase 3 trials and tried to set them into clinical perspective. Furthermore, we will elaborate on updated data on immunotherapeutics in gastroesophageal cancers, since drug approvals may be anticipated before co...
متن کاملRecent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies that originate in the gastrointestinal system. GEP-NETs are typically indolent, but tumors known as "functional" secrete hormones that can lead to a complex of symptoms, including flushing, diarrhea, bronchospasm, and valvular heart disease. Management of patients with GEP-NETs requires a multidisciplinary approach, a...
متن کاملAmerican Society of Clinical Oncology's 2008 Gastrointestinal Cancers Symposium (ASCO GI), January 25-27, 2008, Orlando, Florida.
Should combination or sequential strategies be preferred in colorectal cancer? This was the subject of an evening debate featured at the ASCO GI meeting. The controversy had been sparked by studies published recently in the same issue of The Lancet. The first – the Focus study (Seymour et al., 2007. Lancet 370, 143–152) which compared upfront combination treatment with 5FU (fluorouracil, irinot...
متن کاملAdvancements in the Management of Pancreatic Cancer: 2015 ASCO Gastrointestinal Cancers Symposium (San Francisco, CA, USA. January 15-17, 2015).
Agent Response rate (RR) Median PFS Median OS #344 Pimasertib (Pim) + gemcitabine vs. Placebo + gemcitabine 9.1% both arms 3.7 months vs. 2.8 months (HR: 0.883, 95% CI: 0.549–1.42; P=0.608) 7.3 months vs. 8.3 months #336 IMM-101 + gemcitabine vs. gemcitabine monotherapy NR 4.4 months vs. 2.4 months (P=0.003) 7.2 months vs. 5.6 months
متن کاملTracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
The 2015 Gastrointestinal Cancers Symposium (San Francisco, CA, USA; January 15-17) is the world-class conference co-sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, the American Gastroenterological Association Institute, and the Society of Surgical Oncology, in which the most innovative research results in digestive tract oncology are present...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Geriatric Oncology
سال: 2019
ISSN: 1879-4068
DOI: 10.1016/j.jgo.2019.03.003